Other Information .
−Removed: Trading Arrangements
−Removed: During the Company’s last fiscal quarter, one of the Company’s directors adopted a written plan for the sale of the Company’s common stock set forth in the table below.
−Removed: Type of Trading Arrangement
−Removed: Name and Position Action Adoption
−Removed: Date Rule 10b5-1* Non-
−Removed: Rule 10b5-1** Total Shares of Common Stock to be Sold Expiration Date
−Removed: Deborah Messemer , Director
−Removed: Adoption August 30, 2024 X ― 61,529 June 30, 2025
−Removed: * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
−Removed: ** “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.
−Removed: Table o f Contents
+Added: On May 12, 2025, our Board of Directors approved an approximately 28% reduction in our employee workforce in connection with a reduction in manufacturing operations and reprioritization of resources to focus on our clinical programs.
+Added: We estimate that we will incur approximately $3.3 million in charges related to employee severance payments, benefits and related costs in connection with the workforce reduction.
+Added: All of the estimated charges are expected to result in future cash expenditures.
+Added: We anticipate that the majority of the workforce reduction charges will be incurred in the second quarter of 2025 and that the reduction in workforce will be substantially completed by the end of the second quarter of 2025.
+Added: The estimated charges that we expect to incur are subject to a number of assumptions, and actual results may differ materially from these estimates.
+Added: We may also incur other charges, including cash expenditures, not currently contemplated due to events that may occur as a result of, or that are associated with, the reduction in workforce.
Description of document
8 unchanged sentences
333-227333), filed with the SEC on October 2, 2018).
+Added: 10.1+ Non-employee director compensation policy, as amended.
+Added: 10.2+ Amended and Restated Collaboration and License Agreement, dated January 17, 2024, by and between the Registrant and Notch Therapeutics Inc.
+Added: (incorporated by reference to Exhibit 10.18 to the Registrant ’ s Annual Report on Form 10-K, filed with the SEC on March 14, 2024).
+Added: 10.3+ Strategic Collaboration Agreement, dated January 3, 2024, by and between Foresight Diagnostics, Inc.
+Added: and the Registrant (incorporated by reference to Exhibit 10.30 to the Registrant's Annual Report on Form 10-K, filed with the SEC on March 14, 2024).
+Added: 10.4*‡ Amended and Restated Strategic Collaboration Agreement, dated as of February 19, 2025, by and between the Registrant and Foresight Diagnostics, Inc.
+Added: 10.5+ Non-employee D irector R estricted S tock U nit Grant Notice and Award Agreement , as amended .
+Added: 10.6+ C onsulting Agreement , effective as of August 9 , 20 1 8 , by and between the R egistrant and Bellco Capita l LL C , as amended .
31.1 Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.
9 unchanged sentences
104 The cover page from the Company’s Quarterly Report on Form 10-Q has been formatted in Inline XBRL.
−Removed: Table o f Contents
+Added: + Indicates management contract or compensatory plan.
+Added: * Certain portions of this exhibit (indicated by “[***]”) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both not material and is the type of information that the Registrant treats as private or confidential.
+Added: ‡ Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: November 7, 2024 By:
+Added: May 13, 2025 By:
/s/ David Chang
2 unchanged sentences
(Principal Executive Officer)
−Removed: November 7, 2024 By:
+Added: May 13, 2025 By:
/s/ Geoffrey Parker
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.